Work

The crosstalk between non-coding RNA polymorphisms and resistance to lung cancer therapies

Year: 2023

Type: review

Abstract: Lung cancer (LC) is one of the most common cancer-related mortality in the world. Even with intensive multimodality therapies, lung cancer has a poor prognosis and a high morbidity rate. This review focused on the role of non-coding RNA polymorphisms such as lncRNAs and miRNAs in the resistance to LC therapies, which could open promising avenue for better therapeutic response. Of note, there is currently no valid biomarker to predict lung cancer sensitivity in patients during treatment. Since genetic variations cause many challenges in treating patients, genotyping of known polymorphisms must be thoroughly explored to find desirable treatment platforms. With this knowledge, individualized treatments could become more possible in management of LC.

Source: Heliyon

DOI: 10.1016/j.heliyon.2023.e20652

Authors: Samaneh Mollazadeh, Negar Abdolahzadeh, Meysam Moghbeli, Fatemeh Arab, Ehsan Saburi

Institutions: North Khorasan University of Medical Sciences, Mashhad University of Medical Sciences

Language: English

Topic: Cancer-related molecular mechanisms research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,100